(Q44791042)
Statements
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? (English)
Dennis M Black
Steven R Cummings
Steven Boonen
Felicia Cosman
1 December 2014